Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial

BackgroundDyslipidemia is a major risk factor for atherosclerotic cardiovascular disease and a leading cause of death worldwide. The clinical utility of commonly used lipid-lowering drugs such as statins and fibrates is sometimes limited by the occurrence of various adverse reactions. Recently, berberine (BBR) has received increasing attention as a safer and more cost-effective option to manage dyslipidemia. Thus, a high-quality randomized controlled trial to evaluate the efficacy and safety of BBR in the treatment of dyslipidemia is deemed necessary.Methods/designThis is a randomized, double-blind, and placebo-controlled clinical trial. A total of 118 patients with dyslipidemia will be enrolled in this study and randomized into two groups at a ratio of 1:1. BBR or placebo will be taken orally for 12weeks. The primary outcome is the percentage of low-density lipoprotein cholesterol reduction at week 12. Other outcome measures include changes in other lipid profiles, high sensitivity C-reactive protein, blood pressure, body weight, Bristol Stool Chart, traditional Chinese medicine symptom form, adipokine profiles, and metagenomics of intestinal microbiota. Safety assessment includes general physical examination, blood and urine routine test, liver and kidney function test, and adverse events.DiscussionThis trial may provide high-quality evidence on the efficacy and safety of BBR for dyslipidemia. Importantly, the findings of this trial will help to identify patient and disease characteristics that may predict favorable outcomes of treatment with BBR and optimize its indication for clinical use.Trial registrationChinese Clinical Trial Registry ChiCTR1900021361. Registered on 17 February 2019.

Automated summary

This study is a randomized, double-blind, and placebo-controlled clinical trial to evaluate the efficacy and safety of berberine for dyslipidemia. It aims to determine the effectiveness and safety of berberine in treating dyslipidemia by measuring primary outcomes such as the percentage of low-density lipoprotein cholesterol reduction at week 12.